Bridging science and patients through strategic collaboration
To accelerate the translation of scientific discoveries into better cancer care, Oncode Institute has formed a strategic alliance with the Oncode Accelerator Foundation, coordinating part of the Oncode Accelerator programe.
This alliance unites academic researchers, clinicians, entrepreneurs, and investors around one shared goal: to bring innovative therapies to patients faster and more efficiently.
Oncode Accelerator: Innovating and accelerating the development of new cancer therapies to address unmet medical needs
Oncode Accelerator is a large-scale programe designed to speed up the development of safe, personalized, and effective cancer therapies while strengthening the Dutch oncology innovation ecosystem. It focuses on improving and scaling the preclinical development infrastructure in the Netherlands to make the process of developing new cancer treatments faster and more efficient.
The programe uses three innovation platforms - well-defined Patient Cohorts, patient-derived Organoid models, and Artificial Intelligence - to put patients at the center of the preclinical development process. Expertise from these platforms is integrated into early drug development to accelerate the creation of four common types of therapies that can benefit society.
Oncode Accelerator provides funding, scientific expertise, and access to infrastructure for national and international cancer researchers and drug developers in both academia and industry, helping them deliver new clinical candidates.
The programe is a public-private partnership, funded by the Dutch National Growth Fund (NGF) and private partners, and is coordinated by six partners: Leiden University, Leiden University Medical Center, the Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht, and the Oncode Accelerator Foundation.
Oncode Institute’s Role
As one of the initiators and valorization engine behind Oncode Accelerator, Oncode Institute plays a key role in identifying high-potential research, supporting investigators, and fostering connections between fundamental science and clinical development.
This collaboration allows us to:
- Shorten the time from discovery to application
- De-risk early-stage oncology innovations
- Build public-private partnerships with lasting impact
- Strengthen the Netherlands' position as a global leader in cancer innovation
Together, we aim to create a seamless pathway from lab to patient—aceelerating the translation of breakthroughs into benefits for people living with cancer.